dimiracetam
Small moleculeexperimental
Dimiracetam is a nootropic drug of the racetam family, derivatives of which may have application in the treatment of neuropathic pain. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01135251)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glutamate [NMDA] receptor subunit 3AINHIBITOR
GRIN3A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CN2C(=O)CCC2N1- Mol. weight
- 140.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDimiracetam ↗
- ChEMBLCHEMBL337612 ↗
Also known as
- dihydro-1h-pyrrolo(1,2-a)imidazole-2,5-(3h,6h)-dione
- dimiracetam
- dimiracetam
- dimiracetam
- dimiracetam
- dimiracetam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01444690 | Phase 2 | Jan 1, 2012 | Neurotune AG |
| NCT01135251 | Phase 2 | Oct 1, 2009 | Cross Research S.A., Neurotune AG, Triclinium Clinical Trial Project Management, Triple O Research Institute PA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurotune AG | For profit | 2 | 2 | 1 | 2009 |
| Cross Research S.A. | For profit | 1 | 0 | 1 | 2009 |
| Triclinium Clinical Trial Project Management | For profit | 1 | 0 | 1 | 2009 |
| Triple O Research Institute PA | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1